Literature DB >> 29018163

mtDNA copy number associated with age of onset in familial amyloid polyneuropathy.

Carolina Lemos1,2,3, Manuela Grazina4,5, Diana Santos1,2,3, Maria João Santos4,5, Miguel Alves-Ferreira1,2,3, Teresa Coelho6, Jorge Sequeiros1,2,3,7, Isabel Alonso1,2,7,3, Pedro Oliveira3,8, Alda Sousa1,2,3.   

Abstract

BACKGROUND: Transthyretin-related familial amyloid polyneuropathy (TTR-FAP Val30Met) shows a wide variation in age-at-onset (AO) between generations and genders, as in Portuguese families, where women display a later onset and a larger anticipation (>10 years). Mitochondrial DNA (mtDNA) copy number was assessed to clarify whether it has a modifier effect on AO variability in Portuguese patients.
METHODS: The mtDNA copy number of 262 samples (175 Val30Met TTR carriers and 87 controls (proven Val30Val)) was quantified by quantitative real-time PCR. Statistical analysis was performed using IBM SPSS V.23 software.
RESULTS: This study shows that Val30Met TTR carriers have a significantly higher (p<0.001) mean mtDNA copy number than controls. Furthermore, the highest mtDNA copy number mean was observed in early-onset patients (AO <40 years). Importantly, early-onset offspring showed a significant increase (p=0.002) in the mtDNA copy number, when compared with their late AO parents.
CONCLUSIONS: The present findings suggest, for the first time, that mtDNA copy number may be associated with earlier events and may therefore be further explored as a potential biomarker for follow-up of TTR-FAP Val30Met carriers. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  genetics

Mesh:

Substances:

Year:  2017        PMID: 29018163     DOI: 10.1136/jnnp-2017-316657

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  5 in total

Review 1.  Mitochondrial transfer/transplantation: an emerging therapeutic approach for multiple diseases.

Authors:  Zonghan Liu; Yi Sun; Zhengtang Qi; Lu Cao; Shuzhe Ding
Journal:  Cell Biosci       Date:  2022-05-19       Impact factor: 9.584

2.  Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update.

Authors:  Angela Dispenzieri; Teresa Coelho; Isabel Conceição; Márcia Waddington-Cruz; Jonas Wixner; Arnt V Kristen; Claudio Rapezzi; Violaine Planté-Bordeneuve; Juan Gonzalez-Moreno; Mathew S Maurer; Martha Grogan; Doug Chapman; Leslie Amass
Journal:  Orphanet J Rare Dis       Date:  2022-06-18       Impact factor: 4.303

Review 3.  Transthyretin familial amyloid polyneuropathy: an update.

Authors:  Violaine Plante-Bordeneuve
Journal:  J Neurol       Date:  2017-12-16       Impact factor: 4.849

4.  Ala97Ser transthyretin amyloidosis-associated polyneuropathy, clinical and neurophysiological profiles in a Thai cohort.

Authors:  Nath Pasutharnchat; Chamaiporn Taychargumpoo; Yongkasem Vorasettakarnkij; Jakkrit Amornvit
Journal:  BMC Neurol       Date:  2021-05-22       Impact factor: 2.474

5.  Amyloid fibril composition type is consistent over time in patients with Val30Met (p.Val50Met) transthyretin amyloidosis.

Authors:  Intissar Anan; Ole B Suhr; Katarzyna Liszewska; Jorge Mejia Baranda; Björn Pilebro; Jonas Wixner; Elisabet Ihse
Journal:  PLoS One       Date:  2022-03-31       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.